AG337 and AG331 thymidylate synthase inhibitors data

AGPH presented interim results from a Phase I U.K. study of AG337, a small molecule inhibitor of the TS enzyme, which plays a central role in the proliferation of cancer cells.

A Phase Ia study tested doses of 75, 150, 300, 600, 900 and 1350 mg/m2administered by intravenous infusion over 24 hours. The highest dose resulted in plasma concentrations of drug within the range of levels associated with anti-tumor activity in animal models. With the exception of local irritation at the injection site, the drug was well tolerated by all patients. ...